Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 9/20 | 0.58 |
| ▸ | GPR132 | Q9UNW8 | 3/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1808339 | 1.00 | LPAR1 (0.58) | LPAR1GPR132SCN9ACYP11B1CYP11B2 | |
| SCHEMBL1808335 | 1.00 | LPAR1 (0.58) | LPAR1GPR132SCN9ACYP11B1CYP11B2 | |
| SCHEMBL1808154 | 0.92 | LPAR1 (0.70) | LPAR1GPR132SCN9ACYP11B1CYP11B2 | |
| SCHEMBL1808879 | 0.92 | LPAR1 (0.59) | LPAR1GPR132SCN9ACYP11B1CYP11B2 | |
| SCHEMBL1808882 | 0.92 | LPAR1 (0.59) | LPAR1GPR132SCN9ACYP11B1CYP11B2 | |
| SCHEMBL1808156 | 0.92 | LPAR1 (0.70) | LPAR1GPR132SCN9ACYP11B1CYP11B2 | |
| SCHEMBL1808159 | 0.92 | LPAR1 (0.70) | LPAR1GPR132SCN9ACYP11B1CYP11B2 | |
| SCHEMBL1808880 | 0.92 | LPAR1 (0.59) | LPAR1GPR132SCN9ACYP11B1CYP11B2 | |
| SCHEMBL1810960 | 0.92 | LPAR1 (0.63) | LPAR1GPR132 | |
| SCHEMBL1810959 | 0.92 | LPAR1 (0.63) | LPAR1GPR132 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496556-B1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2018-12-26 | — | — | EP | disclosed |
| US-9018383-B2 | Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2015-04-28 | — | — | US | disclosed |
| US-9018383-B2 | Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2015-04-28 | — | — | US | disclosed |
| US-20140088158-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-03-27 | — | — | US | disclosed |
| US-20140088158-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-03-27 | — | — | US | disclosed |
| US-8618304-B2 | Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2013-12-31 | — | — | US | disclosed |
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-10-18 | — | — | US | disclosed |
| EP-2496556-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011053948-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264790-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | LPAR1 4/4885GPR132 518/4885SCN9A 3363/4885 |
| US-20140088158-A1 | ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | LPAR2, LIPG, EDF1 | LPAR1 4/4885GPR132 518/4885SCN9A 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.